BACKGROUND: Patients with heart failure and preserved ejection fraction (HFpEF) display increased adiposity and multiple comorbidities, factors that in themselves may influence cardiovascular structure and function. This has sparked debate as to whether HFpEF represents a distinct disease or an amalgamation of comorbidities. We hypothesized that fundamental cardiovascular structural and functional alterations are characteristic of HFpEF, even after accounting for body size and comorbidities. METHODS AND RESULTS: Comorbidity-adjusted cardiovascular structural and functional parameters scaled to independently generated and age-appropriate allometric powers were compared in community-based cohorts of HFpEF patients (n=386) and age/sex-matched healthy n=193 and hypertensive, n=386 controls. Within HFpEF patients, body size and concomitant comorbidity-adjusted cardiovascular structural and functional parameters and survival were compared in those with and without individual comorbidities. Among HFpEF patients, comorbidities (obesity, anemia, diabetes mellitus, and renal dysfunction) were each associated with unique clinical, structural, functional, and prognostic profiles. However, after accounting for age, sex, body size, and comorbidities, greater concentric hypertrophy, atrial enlargement and systolic, diastolic, and vascular dysfunction were consistently observed in HFpEF compared with age/sex-matched normotensive and hypertensive. CONCLUSIONS: Comorbidities influence ventricular-vascular properties and outcomes in HFpEF, yet fundamental disease-specific changes in cardiovascular structure and function underlie this disorder. These data support the search for mechanistically targeted therapies in this disease.
BACKGROUND:Patients with heart failure and preserved ejection fraction (HFpEF) display increased adiposity and multiple comorbidities, factors that in themselves may influence cardiovascular structure and function. This has sparked debate as to whether HFpEF represents a distinct disease or an amalgamation of comorbidities. We hypothesized that fundamental cardiovascular structural and functional alterations are characteristic of HFpEF, even after accounting for body size and comorbidities. METHODS AND RESULTS: Comorbidity-adjusted cardiovascular structural and functional parameters scaled to independently generated and age-appropriate allometric powers were compared in community-based cohorts of HFpEF patients (n=386) and age/sex-matched healthy n=193 and hypertensive, n=386 controls. Within HFpEF patients, body size and concomitant comorbidity-adjusted cardiovascular structural and functional parameters and survival were compared in those with and without individual comorbidities. Among HFpEF patients, comorbidities (obesity, anemia, diabetes mellitus, and renal dysfunction) were each associated with unique clinical, structural, functional, and prognostic profiles. However, after accounting for age, sex, body size, and comorbidities, greater concentric hypertrophy, atrial enlargement and systolic, diastolic, and vascular dysfunction were consistently observed in HFpEF compared with age/sex-matched normotensive and hypertensive. CONCLUSIONS: Comorbidities influence ventricular-vascular properties and outcomes in HFpEF, yet fundamental disease-specific changes in cardiovascular structure and function underlie this disorder. These data support the search for mechanistically targeted therapies in this disease.
Authors: Michel Komajda; Peter E Carson; Scott Hetzel; Robert McKelvie; John McMurray; Agata Ptaszynska; Michael R Zile; David Demets; Barry M Massie Journal: Circ Heart Fail Date: 2010-11-10 Impact factor: 8.790
Authors: Michael R MacDonald; Mark C Petrie; Fumi Varyani; Jan Ostergren; Eric L Michelson; James B Young; Scott D Solomon; Christopher B Granger; Karl Swedberg; Salim Yusuf; Marc A Pfeffer; John J V McMurray Journal: Eur Heart J Date: 2008-04-14 Impact factor: 29.983
Authors: Gülmisal Güder; Stefan Frantz; Johann Bauersachs; Bruno Allolio; Christoph Wanner; Michael T Koller; Georg Ertl; Christiane E Angermann; Stefan Störk Journal: Circ Heart Fail Date: 2009-09-24 Impact factor: 8.790
Authors: Sven Meyer; Frank P Brouwers; Adriaan A Voors; Hans L Hillege; Rudolf A de Boer; Ron T Gansevoort; Pim van der Harst; Michiel Rienstra; Isabelle C van Gelder; Dirk J van Veldhuisen; Wiek H van Gilst; Peter van der Meer Journal: Clin Res Cardiol Date: 2014-11-15 Impact factor: 5.460
Authors: Selma F Mohammed; Imad Hussain; Omar F AbouEzzeddine; Omar F Abou Ezzeddine; Hiroyuki Takahama; Susan H Kwon; Paul Forfia; Véronique L Roger; Margaret M Redfield Journal: Circulation Date: 2014-11-12 Impact factor: 29.690
Authors: Barry A Borlaug; Horng Chen; Grace Lin; Margaret M Redfield; Gregory D Lewis; Marc J Semigran; Steven E McNulty; Martin LeWinter; Anita Deswal; Kenneth B Margulies Journal: Circ Heart Fail Date: 2015-07 Impact factor: 8.790
Authors: Robert J Mentz; Jacob P Kelly; Thomas G von Lueder; Adriaan A Voors; Carolyn S P Lam; Martin R Cowie; Keld Kjeldsen; Ewa A Jankowska; Dan Atar; Javed Butler; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor Journal: J Am Coll Cardiol Date: 2014-11-24 Impact factor: 24.094
Authors: Michael Zacharias; Samuel Joffe; Elizabeth Konadu; Theo Meyer; Michael Kiernan; Darleen Lessard; Robert J Goldberg Journal: Int J Cardiol Date: 2015-10-22 Impact factor: 4.164